Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

INTERSTELLAR - Multi-National, Observational, Prospective, Post-Launch, Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice

NCT06314282 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06314282
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06314282 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
INTERSTELLAR - Multi-National, Observational, Prospective, Post-Launch, Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Recruiting
Start date
October 22, 2024
Completion date
December 31, 2027
Enrollment
200 (estimated)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus (sle)